CI

At a glance

ClinicalIndex Comparison Record
Phase 3Terminated
Drug / intervention
Gabapentin (Neurontin)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00317850
NCT00317850Phase 3Terminated
Terminated
CompareCT.gov

Gabapentin for the Relief of Idiopathic Subjective Tinnitus

Washington University School of Medicine·interventional·Posted Apr 25, 2006·Updated Mar 2, 2012

In Brief

A Phase 3 clinical trial evaluating Gabapentin (Neurontin) for Tinnitus. Terminated early.

Signals

Trial was terminated early

Detailed Summary

The specific aim of the Gabapentin for the Relief of Idiopathic Subjective Tinnitus Trial is to assess the therapeutic benefit of Gabapentin (Neurontin®) for subjective idiopathic troublesome tinnitus. We employed a double-blind placebo-controlled randomized clinical trial design to assess the efficacy of Gabapentin. Adults, between the ages of 18 and 70 with idiopathic, subjective, troublesome, unilateral or bilateral, non-pulsatile tinnitus of 6 month's duration or greater and score of 38 or greater on the Tinnitus Handicap Inventory were enrolled.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTinnitus
Countries--
CollaboratorsNational Institute on Deafness and Other Communication Disorders (NIDCD)

Timeline

Phase 3TerminatedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 25, 2006
Enrollment StartApr 1, 2004
Study CompletionFeb 1, 2006
TodayJul 1, 2026
Posted 20.2 years ago

Interventions

Gabapentin (Neurontin)drug